Filing Flows › Lifecore Biomedical (LFCR) › Takeover & LBO
Is Lifecore Biomedical (LFCR) a takeover target?
A leveraged buyout does not work for Lifecore Biomedical on its latest figures: the figures a buyout model needs (revenue, EBITDA, the share count and the price) are not all on file. Latest signal (2026-11-05): As previously disclosed, on September 27, 2026, Lifecore Biomedical, Inc. (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Lifecore Inc. (“Parent”) and Hazel Merger Sub, Inc. (“Merger Sub”) providin.
Why a leveraged buyout does not fit
The buyout model needs Lifecore Biomedical's revenue, EBITDA, share count and share price; not all of them are on file, so it gives no buyout price.
What a takeover could cost
Takeovers in its sector paid a median premium of 35% over the share price before the deal (the middle half 22% to 45%), according to the 15 merger proxies and tender-offer responses on EDGAR that state a premium.
Rumors and deal signals
- 2026-11-05 · 8-K deal · As previously disclosed, on September 27, 2026, Lifecore Biomedical, Inc. (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Lifecore Inc. (“Parent”) and Hazel Merger Sub, Inc. (“Merger Sub”) providin
- 2026-09-28 · deal · Agreed sale to and into the Company at $6.28 cash a share · pending
Lifecore Biomedical's latest quarter
Lifecore Biomedical, Q1 FY27: revenue $25.3M (-19% year over year), operating margin -3.5%, net loss $40.1M, operating cash flow $6.9M. The chart follows the revenue to costs, profit and cash.
Questions
Is Lifecore Biomedical being acquired?
The latest signal on file is from 2026-11-05: As previously disclosed, on September 27, 2026, Lifecore Biomedical, Inc. (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Lifecore Inc. (“Parent”) and Hazel Merger Sub, Inc. (“Merger Sub”) providin. A headline is not a deal; Filing Flows lists the news, 8-K filings and 13D filings about a sale.
Could private equity buy Lifecore Biomedical?
A leveraged buyout does not work for Lifecore Biomedical on its latest figures: the figures a buyout model needs (revenue, EBITDA, the share count and the price) are not all on file. The model gives no buyout price until they are.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.